{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:21:22Z","timestamp":1767147682271,"version":"build-2238731810"},"update-to":[{"DOI":"10.1016\/j.japh.2024.102094","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000}}],"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002596","name":"APhA Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002596","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.japh.2024.102094","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T22:32:49Z","timestamp":1712701969000},"page":"102094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of outpatient pharmacist dispensing in an opioid use disorder clinic"],"prefix":"10.1016","volume":"64","author":[{"given":"Emma","family":"Piehl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8519-0741","authenticated-orcid":false,"given":"Stevie","family":"Veach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Powers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Otting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jess","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linnea A.","family":"Polgreen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2667-7703","authenticated-orcid":false,"given":"Kaley","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8381-7224","authenticated-orcid":false,"given":"Matthew J.","family":"Witry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2024.102094_bib3","series-title":"Opioids: Pharmacology, Abuse, and Addiction","first-page":"315","article-title":"Medication-assisted treatment (MAT) 1: Opioid substitution therapy","author":"Tidder","year":"2022"},{"issue":"7","key":"10.1016\/j.japh.2024.102094_bib4","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajhp\/zxy089","article-title":"The opioid crisis: origins, trends, policies, and the roles of pharmacists","volume":"76","author":"Chisholm-Burns","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"10.1016\/j.japh.2024.102094_bib5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","article-title":"Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009","volume":"103","author":"Schwartz","year":"2013","journal-title":"Am J Public Health"},{"issue":"22","key":"10.1016\/j.japh.2024.102094_bib6","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2014tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.japh.2024.102094_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harv Rev Psychiatry"},{"issue":"5","key":"10.1016\/j.japh.2024.102094_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2146\/news180013","article-title":"Medical treatment is key in battling opioid crisis","volume":"75","author":"Traynor","year":"2018","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.japh.2024.102094_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108729","article-title":"Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden","volume":"224","author":"Kazerouni","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"10.1016\/j.japh.2024.102094_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2839","article-title":"Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US","volume":"3","author":"Qato","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"5","key":"10.1016\/j.japh.2024.102094_bib11","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.japh.2023.06.010","article-title":"Independent community pharmacists\u2019 attitudes and intentions toward dispensing buprenorphine\/naloxone for opioid use disorder","volume":"63","author":"Zalmai","year":"2023","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"suppl 3","key":"10.1016\/j.japh.2024.102094_bib12","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review","volume":"35","author":"Mackey","year":"2020","journal-title":"J\u00a0Gen Intern Med"},{"issue":"4","key":"10.1016\/j.japh.2024.102094_bib13","first-page":"e224","article-title":"Community pharmacists\u2019 knowledge and perceptions of buprenorphine for patients with opioid use disorder","volume":"17","author":"Tutag Lehr","year":"2023","journal-title":"J\u00a0Addict Med"},{"issue":"2","key":"10.1016\/j.japh.2024.102094_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/29767342231215178","article-title":"Relationships between stigma, risk tolerance, and buprenorphine dispensing intentions among community-based pharmacists: results from a national sample","volume":"45","author":"Light","year":"2024","journal-title":"Subst Use Addict J"},{"issue":"5","key":"10.1016\/j.japh.2024.102094_bib15","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.japh.2022.04.019","article-title":"North Carolina community pharmacists\u2019 buprenorphine dispensing practices and attitudes","volume":"62","author":"Carpenter","year":"2022","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2024.102094_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2015.04.009","article-title":"Medicaid coverage of medications to treat alcohol and opioid dependence","volume":"55","author":"Mark","year":"2015","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"2","key":"10.1016\/j.japh.2024.102094_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1331\/JAPhA.2015.14177","article-title":"Physician\u2013pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients","volume":"55","author":"DiPaula","year":"2015","journal-title":"J.\u00a0Am. Pharm. Assoc. (2003)"},{"issue":"12","key":"10.1016\/j.japh.2024.102094_bib20","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1377\/hlthaff.2016.0623","article-title":"Survey highlights differences in Medicaid coverage for substance use treatment and opioid use disorder medications","volume":"35","author":"Grogan","year":"2016","journal-title":"Health Aff. (Millwood)"},{"issue":"17","key":"10.1016\/j.japh.2024.102094_bib18","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/ajhp\/61.17.1816","article-title":"Pharmacist-facilitated enrollment in medication assistance programs in a private ambulatory care clinic","volume":"61","author":"Sarrafizadeh","year":"2004","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.1016\/j.japh.2024.102094_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jac5.1579","article-title":"Pharmacists' role in buprenorphine management for opioid use disorder: a narrative review","volume":"5","author":"Cleary","year":"2022","journal-title":"J\u00a0Am Coll Clin Pharm"},{"key":"10.1016\/j.japh.2024.102094_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"}],"updated-by":[{"DOI":"10.1016\/j.japh.2024.102094","type":"withdrawal","label":"Withdrawal","source":"publisher","updated":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000}}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124001146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319124001146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T19:31:59Z","timestamp":1737660719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319124001146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1544319124001146"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2024.102094","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of outpatient pharmacist dispensing in an opioid use disorder clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2024.102094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102094"}}